Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

This study has suspended participant recruitment.
Sponsor:
Collaborators:
Southwest Oncology Group
Cancer and Leukemia Group B
NCIC Clinical Trials Group
Children's Oncology Group
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00003641
First received: November 1, 1999
Last updated: July 11, 2012
Last verified: July 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)